MHRA drug alert

Posted 8 July 2020

Date: 08 Jul 2020

Type: FSRH Clinical Guidance and Clinical Statements

The MHRA (Medicines & Healthcare products Regulatory Agency) has issued a drug alert for two batches of Depo Provera® 150mg/ml distributed since February 2020 by Drugsrus Ltd (Marketing Authorisation Holder Tenolol Ltd) because there is a typographical error on vial labels. The FSRH CEU considers that there is no apparent risk of harm to users.

In the affected batches (AT0604 & X44095), vials are labelled “Depo Provera® 150mg/ml (methylprednisolone acetate)” rather than medroxyprogesterone acetate. The vials contain medroxyprogesterone acetate 150mg/ml as intended, and the packaging is correctly labelled. The MHRA states that there are no concerns with the quality, safety or efficacy of the product and that affected batches will not, therefore, be recalled. No more affected stock will be distributed.

Enquiries to or 020 8423 3800.